[Retracted] Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma

Table 3

Comparison of serum tumor markers between the two groups ().

Group	HE4 (pmol/l)		CA125 (U/ml)		CA199 (IU/ml)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Observation group ()		^a		^a		^a
Control group ()		^a		^a		^a
	0.091	6.871	0.279	14.772	0.249	8.445
	0.928	<0.001	0.781	<0.001	0.804	<0.001

Note: compared with before treatment in the same group, ^a.